share_log

Boryung Announces Winners of the 3rd Humans In Space Challenge

Boryung Announces Winners of the 3rd Humans In Space Challenge

博隆公司宣布第三届太空中的人类挑战赛获奖者
PR Newswire ·  12/18 22:00

Paving the Way as a Global Leader in Space Healthcare

作为全球空间医疗保健领域的领导者,开辟新天地

- Introducing of a new funding model to support space experiments and strengthen research in space healthcare

- 引入新融资模式以支持空间实验并加强空间医疗保健研究

- Hosted the final round of the Humans In Space Challenge at the 75th International Astronautical Congress

- 在第75届国际宇航联合会大会上举办了空间人类挑战赛的决赛

SEOUL, South Korea, Dec. 18, 2024 /PRNewswire/ -- On December 18, Boryung announced the final winners of the 3rd Humans In Space (HIS) Challenge.

韩国首尔,2024年12月18日 /美通社/ -- 12月18日,博隆公司宣布第三届人类在空间(HIS)挑战赛的最终获胜者。

Now in its 3rd year, the HIS Challenge is a global space healthcare competition initiated in 2022. The program aims to gather innovative ideas to address healthcare challenges arising during space exploration and solve healthcare problems on Earth by leveraging the space environment. Outstanding teams are selected and offered investment opportunities through this initiative.

人类在空间挑战赛已进入第三年, 是一项始于2022年的全球空间医疗保健竞赛。该项目旨在收集创新理念,以应对空间探索中的医疗保健挑战,并通过利用空间环境解决地球上的医疗保健问题。优秀团队将通过该项倡议被选中并获得投资机会。

A panel of judges is evaluating the final round of the HIS Challenge held in 2024 IAC, Milan, Italy
评审团正在评估于2024年意大利米兰国际宇航大会上举办的人类在空间挑战赛决赛
Prometheus Life Technologies, the final winner of the 3rd HIS Challenge, is presenting at the final stage
第三届人类在空间挑战赛的最终获胜者,普罗米修斯生命技术公司正在进行最终展示

This year, the HIS Challenge introduced significant changes to its prize structure compared to last year. While it provided equity investments for winning startups and research funding for research teams in 2023, it has expanded its offerings to include Orbital Launch Funding (OLF) in addition to equity investments this year. This investment structure is designed to attract innovative space healthcare research ideas to the Humans In Space platform and drive orbital experimentation.

今年,人类在空间挑战赛的奖金结构与去年相比发生了重大变化。虽然它在2023年为获胜的初创企业提供了股权投资和为研究团队提供了研究资金,但今年的奖金设置已扩展到包括轨道发射资金(OLF)作为股权投资的一部分。这一投资结构旨在吸引创新的空间医疗研究理念参与人类在空间平台,并推动轨道实验。

The OLF aims to provide selected teams, regardless of their application type, the opportunity to send their experiments to the International Space Station (ISS) for testing in an actual space environment. Among the finalists, teams capable of conducting space experiments within a short-term period (18 months) are selected as the final winners. Meanwhile, others needing additional preparation are selected as the HIS Catalyst group. Both groups will receive support to advance their space experiments. This year, the OLF category attracted over 70 teams from 11 countries, including South Korea, the United States, Canada, Germany, and the United Kingdom, highlighting a highly competitive field.

OLF旨在为所有申请类型的选定团队提供机会,将他们的实验发送到国际空间站(ISS),以在实际的太空环境中进行测试。在入围的团队中,能够在短期内(18个月)进行太空实验的团队被选为最终赢家。同时,需要额外准备的其他团队被选为HIS Catalyst小组。两个团队都将获得支持,以推进他们的太空实验。今年,OLF类别吸引了来自11个国家的70多支团队,包括韩国、美国、加拿大、德国和英国,突显出一个竞争激烈的领域。

A total of 56 judges from esteemed organizations, including NASA, the French Institute for Space Medicine and Physiology (MEDES), the Harvard Center for Space Medicine Research, Axiom Space, and Redwire, conducted the application and final evaluation. In October, 11 startups and researchers advanced to the final round and competed in the final stage at the 75th International Astronautical Congress (IAC) held in Milan, Italy. A panel of 22 judges selected 4 teams of the final winners and 2 teams of the HIS Catalyst through the evaluation based on importance, scalability, feasibility, and the validity of the expected outcomes.

来自知名机构的共56名评委,包括NASA、法国空间医学和生理学研究所(MEDES)、哈佛空间医学研究中心、Axiom Space和Redwire,进行了申请和最终评估。10月,11家初创企业和研究人员晋级到决赛,并在意大利米兰举行的第75届国际宇航大会(IAC)进入最后阶段进行竞争。22名评委根据重要性、可扩展性、可行性和预期结果的有效性进行评估,选出了4支最终获胜团队和2支HIS Catalyst团队。

In the equity investment group, Exobiosphere, a Luxembourg-based startup providing services to validate drug candidates using microgravity; Prometheus Life Technologies, a Swiss-based startup producing high-quality organoids in space; Ejenta, a U.S.-based startup offering AI-powered remote health monitoring and diagnostic solutions for astronauts, will receive USD 50,000 in funding, respectively.

在股权投资组中,总部位于卢森堡的初创公司Exobiosphere,提供利用微重力验证药物候选者的服务;总部位于瑞士的初创公司Prometheus Life Technologies,在太空中生产高质量的类器官;总部位于美国的初创公司Ejenta,提供人工智能驱动的宇航员远程健康监测和诊断解决方案,将分别获得50,000美元的资助。

In the OLF group, Dr. Charles Chiu's team from the University of California, San Francisco, developing diagnostic solutions for infectious diseases in space, was selected to receive up to USD 250,000 in funding. Through this investment, Dr. Chiu's experiment will be launched into space within the next 18 months.

在OLF小组中,加州大学旧金山分校的Dr. Charles Chiu团队开发用于太空中感染疾病的诊断解决方案,获得了最高可达250,000美元的资助。通过这项投资,Dr. Chiu的实验将在未来18个月内发射到太空。

In the HIS Catalyst group, Scott Ritter from the German Aerospace Agency (DLR), who developed a portable diagnostic tool for Spaceflight-Associated Neuro-Ocular Syndrome (SANS), and Dr. JangKeun Kim from South Korea, who is studying genetic changes in microgravity, were selected. They will undergo a one-year preparation process to meet the requirements of the OLF category, and will be eligible to receive OLF support if they fulfill these conditions.

在HIS Catalyst小组中,来自德国航空航天局(DLR)的Scott Ritter开发了一种便携式诊断工具,用于航天相关神经眼症(SANS),以及来自韩国的Dr. JangKeun Kim,他正在研究微重力下的基因变化。他们将接受为期一年的准备过程,以满足OLF类别的要求,如果满足这些条件,将有资格获得OLF压力位。

Teams selected for equity investment and OLF will receive funding tailored to their specific conditions to accelerate their space business and research. All selected teams, including those in the HIS Catalyst group, will attend the HIS Accelerator Program, which provides mentorship and technical support to advance their research and prepare for space experiments. Moreover, they will gain opportunities to collaborate with various partners within the HIS ecosystem.

被选中进行股权投资和OLF的团队将获得量身定制的资金,以加速他们的太空业务和研究。所有被选中的团队,包括HIS Catalyst小组的成员,将参加HIS加速器项目,该项目提供指导和技术支持,以推进他们的研究并为太空实验做准备。此外,他们将获得与HIS生态系统内各种合作伙伴合作的机会。

Jack Lim, the Executive Director of Boryung's Strategic Investment Division, stated, "As we operate the 3rd year of the HIS Challenge program, we have observed both the program's expansion and the increasing professionalism and technical expertise of its applicants." He added, "This year's program holds significant meaning as we collaborated with a panel of judges specializing in space healthcare and engaged with high-caliber researchers and entrepreneurs dedicated to solving critical problems. With growing interest and expectations for this program within the space healthcare industry, we are committed to building a global ecosystem for space healthcare."

Boryung战略投资部执行董事Jack Lim表示:“在我们进行HIS挑战项目的第三年时,我们观察到该项目的扩展以及申请者专业性和技术专长的提升。”他补充道:“今年的项目具有重要意义,因为我们与专注于太空医疗的评审小组合作,并与致力于解决关键问题的高水平研究人员和企业家进行交流。随着太空医疗行业对此项目的兴趣和期望不断增加,我们致力于建立全球太空医疗生态系统。”

Meanwhile, at the 75th IAC, Boryung featured an engaging Astronaut Talk Session with Koichi Wakata, the Japanese astronaut with the most spaceflights, who shared insights on space healthcare and received the Creative Booth Award for its innovative exhibit showcasing space medicine and healthcare advancements. Furthermore, Boryung signed MOUs with key partners, including Intuitive Machines and the German Aerospace Center (DLR), to advance space healthcare research and solidify its role in fostering a global space healthcare ecosystem.

与此同时,在第75届国际宇航大会上,Boryung举办了一场引人入胜的宇航员讲座,邀请日本宇航员Wakata Koichi,他是进行太空飞行最多的宇航员,分享了关于太空医疗的见解,并因其展示太空医学和医疗进展的创新展品获得了创意展位奖。此外,Boryung与包括Intuitive Machines和德国航空航天中心(DLR)在内的关键合作伙伴签署了谅解备忘录,以推进太空医疗研究并巩固其在促进全球太空医疗生态系统中的角色。

SOURCE Boryung

来源:保龄(Boryung)

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想让贵公司的资讯在PRNEWSWIRE.COM上特色展示吗?

440k+
440k+

Newsrooms &
新闻编辑室和

Influencers
意见领袖
9k+
9k+

Digital Media
数字媒体

Outlets
Outlets
270k+
270k+

Journalists
记者

Opted In
已选择加入
GET STARTED
开始
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发